{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:24:50Z","timestamp":1794554690200,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014651","name":"Lush","doi-asserted-by":"publisher","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/100014651","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preclinical evidence used to support first-in-human (FIH) decisions is often assembled through isolated assessment tools that improve individual parts of translational practice but do not preserve assumptions, uncertainty, and decision intent across discovery-to-clinic handoffs. We therefore reviewed structured translational assessment instruments designed to inform preclinical-to-human decision-making and examined whether the published landscape already contains the components needed for decision-grade evidence integration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>We conducted a scoping review informed by PRISMA-ScR principles to identify peer-reviewed publications describing structured assessment instruments intended to support preclinical-to-clinical translation decisions. Searches were performed in PubMed and complemented by citation snowballing. Nineteen distinct instruments were identified and mapped across the preclinical-to-FIH pathway. The landscape showed clear strengths in model-selection support, reporting quality, risk-of-bias control, and mechanistic structuring of translational claims. However, recurrent limitations were also evident. Few instruments explicitly benchmark performance against downstream human outcomes. Uncertainty associated with evidence generated at one stage is often not explicitly propagated to later stages of the research and decision-making process. Outputs are rarely designed as reusable governance artefacts with explicit context of use, decision owner, breach conditions, and update triggers. The ecosystem is therefore stronger in decision-grade evidence production than in decision-grade evidence integration. Based on this synthesis, we derive a conceptual interoperability framework in which evidence-facing outputs remain source-traceable and uncertainty-aware, while decision-facing outputs are released only within defined governance gates. Within such a framework, AI is most defensible as a constrained support layer for retrieval-grounded extraction, normalization, and interoperability, rather than as an autonomous decision-maker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Short conclusion<\/jats:title>\n                    <jats:p>Current translational practice is limited less by the absence of assessment instruments than by weak interoperability between them. A staged, uncertainty-aware workflow that preserves assumptions and decision logic across handoffs could improve the auditability and reuse of preclinical evidence for FIH governance. Whether such workflows improve predictive performance or downstream clinical decision quality remains to be tested prospectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08604-1","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:23:22Z","timestamp":1783959802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Translational assessment instruments for preclinical to first-in-human decision-making: a scoping review"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3903-4163","authenticated-orcid":false,"given":"Marco","family":"Straccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"David Mawufemor","family":"Azilagbetor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celean","family":"Camp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme S.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Garcia-Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Gastaldello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurinchi","family":"Gurusamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merel J.","family":"Ritskes-Hoitinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Tagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pistollato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"8604_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/clpt.2009.295","volume":"87","author":"JA DiMasi","year":"2010","unstructured":"DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs. Clin Pharmacol Ther. 2010;87:272\u20137. https:\/\/doi.org\/10.1038\/clpt.2009.295.","journal-title":"Clin Pharmacol Ther"},{"key":"8604_CR2","doi-asserted-by":"publisher","first-page":"9537","DOI":"10.1038\/s41467-025-64552-2","volume":"16","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhang Y, Xu H, Chen Z, Huang S, Li Y, et al. Dynamic clinical trial success rates for drugs in the 21st century. Nat Commun. 2025;16:9537. https:\/\/doi.org\/10.1038\/s41467-025-64552-2.","journal-title":"Nat Commun"},{"key":"8604_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/23288604.2015.1091538","volume":"1","author":"S Salas-Vega","year":"2015","unstructured":"Salas-Vega S, Haimann A, Mossialos E. Big Data and Health Care: Challenges and Opportunities for Coordinated Policy Development in the EU. Health Syst Reform. 2015;1:285\u2013300. https:\/\/doi.org\/10.1080\/23288604.2015.1091538.","journal-title":"Health Syst Reform"},{"key":"8604_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40290-020-00343-y","volume":"34","author":"MC Grabb","year":"2020","unstructured":"Grabb MC, Hillefors M, Potter WZ. The NIMH \u2018Fast-Fail Trials\u2019 (FAST) Initiative: Rationale, Promise, and Progress. Pharm Med. 2020;34:233\u201345. https:\/\/doi.org\/10.1007\/s40290-020-00343-y.","journal-title":"Pharm Med"},{"key":"8604_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20\u201333. https:\/\/doi.org\/10.1016\/j.jhealeco.2016.01.012.","journal-title":"J Health Econ"},{"key":"8604_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov. 2010;9:203\u201314. https:\/\/doi.org\/10.1038\/nrd3078.","journal-title":"Nat Rev Drug Discov"},{"key":"8604_CR7","doi-asserted-by":"publisher","unstructured":"Pistollato F, Furtmann F, Straccia M, Avey M, Azilagbetor DM, Camp C, et al. Evaluating the translational value of preclinical models: Available tools and frameworks, challenges and strategies. Altern Lab Anim. 2025. https:\/\/doi.org\/10.1177\/02611929251398821.","DOI":"10.1177\/02611929251398821"},{"key":"8604_CR8","doi-asserted-by":"publisher","unstructured":"Anna J, van der Zalm AJ, van der Zalm Jos\u00e9 G, Barroso P, Browne P, et al. A framework for establishing scientific confidence in new approach methodologies. Arch Toxicol. 2022; https:\/\/doi.org\/10.1007\/s00204-022-03365-4.","DOI":"10.1007\/s00204-022-03365-4"},{"key":"8604_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17:167\u201381. https:\/\/doi.org\/10.1038\/nrd.2017.244.","journal-title":"Nat Rev Drug Discov"},{"key":"8604_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12967-022-03849-y","volume":"21","author":"C Chen","year":"2023","unstructured":"Chen C, Zhou X, Lavezzi SM, Arshad U, Sharma R. Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper. J Transl Med. 2023;21:17. https:\/\/doi.org\/10.1186\/s12967-022-03849-y.","journal-title":"J Transl Med"},{"key":"8604_CR11","doi-asserted-by":"publisher","first-page":"e000004","DOI":"10.1136\/bmjos-2018-000004","volume":"2","author":"J Vollert","year":"2018","unstructured":"Vollert J, Schenker E, Macleod M, Bespalov A, Wuerbel H, Michel MC, et al. Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals. BMJ Open Sci. 2018;2:e000004.","journal-title":"BMJ Open Sci"},{"key":"8604_CR12","doi-asserted-by":"publisher","unstructured":"Ferreira S, Veening-Griffioen G, Boon DH, Moors WPC, Gispen-de Wied EHM, Schellekens CC et al. H, A standardised framework to identify optimal animal models for efficacy assessment in drug development. PLoS ONE. 2019;14:e0218014. https:\/\/doi.org\/10.1371\/journal.pone.0218014.","DOI":"10.1371\/journal.pone.0218014"},{"key":"8604_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0023677217724823","volume":"52","author":"AJ Smith","year":"2018","unstructured":"Smith AJ, Clutton RE, Lilley E, Hansen KEA, Brattelid T. PREPARE: guidelines for planning animal research and testing. Lab Anim. 2018;52:135\u201341. https:\/\/doi.org\/10.1177\/0023677217724823.","journal-title":"Lab Anim"},{"key":"8604_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.joca.2016.10.016","volume":"25","author":"MM Smith","year":"2017","unstructured":"Smith MM, Clarke EC, Little CB. Considerations for the design and execution of protocols for animal research and treatment to improve reproducibility and standardization: DEPART well-prepared and ARRIVE safely. Osteoarthritis Cartilage. 2017;25:354\u201363. https:\/\/doi.org\/10.1016\/j.joca.2016.10.016.","journal-title":"Osteoarthritis Cartilage"},{"key":"8604_CR15","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol United States. 2020;18:e3000411. https:\/\/doi.org\/10.1371\/journal.pbio.3000411.","journal-title":"PLoS Biol United States"},{"key":"8604_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/j.1476-5381.2010.01128.x","volume":"162","author":"CR Hooijmans","year":"2011","unstructured":"Hooijmans CR, de Vries R, Leenaars M, Curfs J, Ritskes-Hoitinga M. Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines. Br J Pharmacol. 2011;162:1259\u201360. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01128.x.","journal-title":"Br J Pharmacol"},{"key":"8604_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41573-020-0087-3","volume":"20","author":"CH Emmerich","year":"2021","unstructured":"Emmerich CH, Gamboa LM, Hofmann MC, Bonin-Andresen M, Arbach O, Schendel P, et al. Improving target assessment in biomedical research: the GOT-IT recommendations. Nat Rev Drug Discov Nat Publishing Group UK Lond. 2021;20:64\u201381.","journal-title":"Nat Rev Drug Discov Nat Publishing Group UK Lond"},{"key":"8604_CR18","doi-asserted-by":"crossref","unstructured":"Bespalov A, Bernard R, Gilis A, Gerlach B, Guillen J, Castagne V, et al. Introduction to the EQIPD quality system. eLife. 2021;10:e63294.","DOI":"10.31219\/osf.io\/ng32b"},{"key":"8604_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/0023677220968583","volume":"55","author":"M Eggel","year":"2021","unstructured":"Eggel M, W\u00fcrbel H. Internal consistency and compatibility of the 3Rs and 3Vs principles for project evaluation of animal research. Lab Anim. 2021;55:233\u201343. https:\/\/doi.org\/10.1177\/0023677220968583.","journal-title":"Lab Anim"},{"key":"8604_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43. https:\/\/doi.org\/10.1186\/1471-2288-14-43.","journal-title":"BMC Med Res Methodol"},{"key":"8604_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/02611929251319265","volume":"53","author":"JP Dukes","year":"2025","unstructured":"Dukes JP, Beale A, Camp C. Reviewing Current Guidance for the \u2018R\u2019 of Replacement and Rethinking it with the \u2018Replacement Checklist\u2019. Altern Lab Anim. 2025;53:72\u201383. https:\/\/doi.org\/10.1177\/02611929251319265.","journal-title":"Altern Lab Anim"},{"key":"8604_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/ilar\/ilac004","volume":"62","author":"J Storey","year":"2021","unstructured":"Storey J, Gobbetti T, Olzinski A, Berridge BR. A Structured Approach to Optimizing Animal Model Selection for Human Translation: The Animal Model Quality Assessment. ILAR J. 2021;62:66\u201376. https:\/\/doi.org\/10.1093\/ilar\/ilac004.","journal-title":"ILAR J"},{"key":"8604_CR23","doi-asserted-by":"publisher","first-page":"e10673","DOI":"10.7717\/peerj.10673","volume":"9","author":"KS Gurusamy","year":"2021","unstructured":"Gurusamy KS, Moher D, Loizidou M, Ahmed I, Avey MT, Barron CC, et al. Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation. PeerJ. 2021;9:e10673. https:\/\/doi.org\/10.7717\/peerj.10673.","journal-title":"PeerJ"},{"key":"8604_CR24","doi-asserted-by":"publisher","unstructured":"Hooijmans CR, De Vries RBM, Ritskes-Hoitinga M, Rovers MM, Leeflang MM, IntHout J et al. J <>Minnerup editor 2018 Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. PLoS ONE 13 e0187271 https:\/\/doi.org\/10.1371\/journal.pone.0187271.","DOI":"10.1371\/journal.pone.0187271"},{"key":"8604_CR25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.medj.2024.07.014","volume":"5","author":"J Kimmelman","year":"2024","unstructured":"Kimmelman J, Bodilly Kane P, Bicer S, Carlisle BG. Preclinical assessment for translation to humans: The PATH approach for assessing supporting evidence for early-phase trials and innovative care. Med N Y N. 2024;5:1227\u201336. https:\/\/doi.org\/10.1016\/j.medj.2024.07.014.","journal-title":"Med N Y N"},{"key":"8604_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.vascn.2009.05.011","volume":"60","author":"J-P Valentin","year":"2009","unstructured":"Valentin J-P, Bialecki R, Ewart L, Hammond T, Leishmann D, Lindgren S, et al. A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods. 2009;60:152\u20138. https:\/\/doi.org\/10.1016\/j.vascn.2009.05.011.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"8604_CR27","doi-asserted-by":"publisher","first-page":"e0220325","DOI":"10.1371\/journal.pone.0220325","volume":"14","author":"GS Ferreira","year":"2019","unstructured":"Ferreira GS, Veening-Griffioen DH, Boon WPC, Moors EHM, Gispen-de Wied CC, Schellekens H, et al. Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development. PLoS ONE. 2019;14:e0220325. https:\/\/doi.org\/10.1371\/journal.pone.0220325.","journal-title":"PLoS ONE"},{"key":"8604_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12967-017-1329-y","volume":"15","author":"A Wendler","year":"2017","unstructured":"Wendler A, Wehling M. Translatability score revisited: differentiation for distinct disease areas. J Transl Med. 2017;15:226. https:\/\/doi.org\/10.1186\/s12967-017-1329-y.","journal-title":"J Transl Med"},{"key":"8604_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrd2898","volume":"8","author":"M Wehling","year":"2009","unstructured":"Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov. 2009;8:541\u20136. https:\/\/doi.org\/10.1038\/nrd2898.","journal-title":"Nat Rev Drug Discov"},{"key":"8604_CR30","doi-asserted-by":"publisher","first-page":"D1302","DOI":"10.1093\/nar\/gkaa1027","volume":"49","author":"D Ochoa","year":"2021","unstructured":"Ochoa D, Hercules A, Carmona M, Suveges D, Gonzalez-Uriarte A, Malangone C, et al. Open Targets Platform: supporting systematic drug-target identification and prioritisation. Nucleic Acids Res. 2021;49:D1302\u201310. https:\/\/doi.org\/10.1093\/nar\/gkaa1027.","journal-title":"Nucleic Acids Res"},{"key":"8604_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41573-022-00552-x","volume":"21","author":"JW Scannell","year":"2022","unstructured":"Scannell JW, Bosley J, Hickman JA, Dawson GR, Truebel H, Ferreira GS, et al. Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nat Rev Drug Discov. 2022;21:915\u201331. https:\/\/doi.org\/10.1038\/s41573-022-00552-x.","journal-title":"Nat Rev Drug Discov"},{"key":"8604_CR32","unstructured":"Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September. 2010 on the Protection of Animals Used for Scientific Purposes [Internet]. European Union; 2010 [cited 2026 Jan 20]. http:\/\/data.europa.eu\/eli\/dir\/2010\/63\/2019-06-26. Accessed 20 Jan 2026."},{"key":"8604_CR33","doi-asserted-by":"publisher","first-page":"e71601","DOI":"10.7554\/eLife.71601","volume":"10","author":"TM Errington","year":"2021","unstructured":"Errington TM, Mathur M, Soderberg CK, Denis A, Perfito N, Iorns E, et al. Investigating the replicability of preclinical cancer biology. eLife. 2021;10:e71601. https:\/\/doi.org\/10.7554\/eLife.71601.","journal-title":"eLife"},{"key":"8604_CR34","doi-asserted-by":"publisher","unstructured":"Wendler A, Wehling M. Translatability scoring in prospective and retrospective COVID drug development cases. 2023; https:\/\/doi.org\/10.1007\/s00228-023-03517-0.","DOI":"10.1007\/s00228-023-03517-0"},{"key":"8604_CR35","doi-asserted-by":"publisher","first-page":"e2350688","DOI":"10.1001\/jamanetworkopen.2023.50688","volume":"7","author":"CJ Vorland","year":"2024","unstructured":"Vorland CJ, Brown AW, Kilicoglu H, Ying X, Mayo-Wilson E. Publication of Results of Registered Trials With Published Study Protocols, 2011\u20132022. JAMA Netw Open. 2024;7:e2350688. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50688.","journal-title":"JAMA Netw Open"},{"key":"8604_CR36","doi-asserted-by":"publisher","unstructured":"Boccardi M, Gold M, Mahant V, Marincola FM, Gunn A. Why should academia care about the Target Product Profile? J Transl Med. 2024;22:716. https:\/\/doi.org\/10.1186\/s12967-024-05520-0.","DOI":"10.1186\/s12967-024-05520-0"},{"key":"8604_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12967-022-03344-4","volume":"20","author":"S Bockhold","year":"2022","unstructured":"Bockhold S, Foley SJ, Rainford LA, Corridori R, Eberstein A, Hoeschen C, et al. Exploring the translational challenge for medical applications of ionising radiation and corresponding radiation protection research. J Transl Med. 2022;20:137. https:\/\/doi.org\/10.1186\/s12967-022-03344-4.","journal-title":"J Transl Med"},{"key":"8604_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12967-021-02910-6","volume":"19","author":"D Hartl","year":"2021","unstructured":"Hartl D, De Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, et al. Translational precision medicine: an industry perspective. J Transl Med. 2021;19:245. https:\/\/doi.org\/10.1186\/s12967-021-02910-6.","journal-title":"J Transl Med"},{"key":"8604_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12967-019-02205-x","volume":"18","author":"P Pound","year":"2020","unstructured":"Pound P, Ritskes-Hoitinga M. Can prospective systematic reviews of animal studies improve clinical translation? J Transl Med. 2020;18:15. https:\/\/doi.org\/10.1186\/s12967-019-02205-x.","journal-title":"J Transl Med"},{"key":"8604_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-019-1976-2","volume":"17","author":"CHC Leenaars","year":"2019","unstructured":"Leenaars CHC, Kouwenaar C, Stafleu FR, Bleich A, Ritskes-Hoitinga M, De Vries RBM, et al. Animal to human translation: a systematic scoping review of reported concordance rates. J Transl Med. 2019;17:223. https:\/\/doi.org\/10.1186\/s12967-019-1976-2.","journal-title":"J Transl Med"},{"key":"8604_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/0023677216639470","volume":"50","author":"M Chlebus","year":"2016","unstructured":"Chlebus M, Guillen J, Prins J-B. Directive 2010\/63\/EU: facilitating full and correct implementation. Lab Anim. 2016;50:151\u2013151. https:\/\/doi.org\/10.1177\/0023677216639470.","journal-title":"Lab Anim"}],"updated-by":[{"DOI":"10.1186\/s12967-026-09140-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:00:00Z","timestamp":1794441600000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08604-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08604-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08604-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:30:30Z","timestamp":1794551430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08604-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8604"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08604-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article updated to correct Fig. 1.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-026-09140-8","URL":"https:\/\/doi.org\/10.1186\/s12967-026-09140-8","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS and FR are employed by FRESCI by Science & Strategy SL. GSF is employed by GlaxoSmithKline. FP is employed by Humane World for Animals. The authors declare no other competing interests relevant to this work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1266"}}